Alzheimer's Therapeutics in Asia-Pacific Market Analysis and Treatment, 2021: Hexa Reports

Hexa Reports
Market Research Reports and Insightful Company Profiles

Alzheimer's Therapeutics in Asia-Pacific Market Size,
Share, Growth, Treatment, Analysis, Symptoms, Emerging
Trends and Opportunities to 2021

Alzheimer’s Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Growing
Awareness and Expected Launch of Disease Modifying Therapies
Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by
cognitive impairment, memory loss and functional decline. Symptoms typically begin to first occur in
patients in their mid-sixties, appearing in varying stages. The pathological features of AD comprise
histopathological changes within the brain.
Browse Detail Report With TOC @
Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia,
whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases
of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.
Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of
drugs in the pipeline is considerable, at 559. The majority of the pipeline products are novel, and there

Hexa Reports
Market Research Reports and Insightful Company Profiles
are only seven repositioned drugs and five generic drugs. This shows progression in terms of the
different molecules being developed as therapeutic agents within the AD pipeline.
The AD market has a lack of therapeutic options.
 Which classes of drug dominate the market?
 What newly approved therapies have entered the market?
 How do the leading marketed therapies compare clinically?
 How will the new therapies be positioned in the treatment of AD?
 How have selected late-stage pipeline therapies performed in...